HomeAgenda

Project cooperationUpdated on 15 September 2025

Therapeutic for lung injury (ARDS, IPF) using MSC-derived Extracellular Vesicles(

About

EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.

EXP01 is a disease-modifying MSC-EV therapy for IPF/ARDS with dual anti-inflammatory/anti-fibrotic activity.

In vivo, it improved fibrosis (Ashcroft) and outperformed nintedanib at 20× the approved dose in IPF; in ARDS, a single dose cut BALF leukocytes by ~50%, comparable to a steroid at 30×.

Repeat-dose tox to date is favorable. The MoA involves a published miR-4516 anti-fibrotic pathway; preconditioning enriches active cargo and miR-4516 serves as a QC marker; composition patent pending (WO/2024/242132).

FDA pre-IND supports the ARDS nonclinical plan; Phase 1/2a PoC is targeted for 2027.

We seek co-development and out-licensing partners.

Stage

  • Planning

Type

  • Research
  • Technical
  • Financing

Organisation

EXORPHIA, INC.

Company (SME/startup) / 中小企業・スタートアップ

Tokyo, Japan